Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »

The paper "Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase” was presented at the American Association for Cancer Research (AACR) meeting by Panacea Pharmaceuticals on April 3. Read More »

Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »

Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »

AbbVie has joined three other pharmaceutical companies in the Oncology Research Information Exchange Network Avatar Research Program. Read More »

Cumberland Pharmaceuticals Inc.'s open label multicenter study, published in Drug Design, Development and Therapy, supports the efficacy and use of Vaprisol Injection for treating hyponatremic patients with severe hepatic impairment. Read More »

Alkermes PLC has launched a Phase 3 study for its product ALKS 8700 – a novel, oral monomethyl fumarate drug in development that will be used for patients with relapsing forms of multiple sclerosis. Read More »

Sanofi Healthcare, the company behind Xyzal Allergy 24HR, recently announced the results of an allergy-related social experiment involving 160 participants who wore wearable devices for 30 days to track sleep and activity. Read More »

In honor of Multiple Sclerosis Awareness Month, Acorda Therapeutics recently launched a new Alexa skill called MS Awareness Facts that will help Amazon Alexa users learn more about the chronic disease and its symptoms.   Read More »

Takeda Pharmaceuticals U.S.A. Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd., is collaborating with Cognition Kit Ltd., a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Ltd., to pilot the use of an Apple Watch app that assesses cognitive function in patients with Major Depressive Disorder. Read More »

BioPharm X Corp., a specialty pharmaceutical company focused on the dermatology market, recently shared early clinical and pre-clinical data for BPX-01 topical gel at the 2017 American Academy of Dermatology (AAD) Annual Meeting. Read More »

Incyte Corp. will conduct a multi-year research project in conjunction with the Abramson Cancer Center at the University of Pennsylvania aimed at advancing the understanding of cancer biology. Read More »

SPX-101, a new compound designed by Spyryx Biosciences, recently passed a Phase 1 study for the treatment of severe lung disease, including cystic fibrosis. Read More »

Acorda Therapeutics' CVT-301, a drug used in treating people with Parkinson’s disease, showed significant improvement in motor functions during a Phase 3 clinical trial. Read More »

Global pharmaceutical leader Allergan is launch a new campaign to bring awareness to blindness, and commit to fighting preventable blindness in the United States in its new See America initiative. Read More »

Cumberland Pharmaceuticals Inc.'s recent clinical study showed its Caldolor Injection (ibuprofen) to be a safe and effective source of fever reduction in hospitalized pediatric use. Read More »

Dr. Bernie Zeiher, president of development at Astellas Pharma, recently addressed the use of biomarkers in the development of precise and specific treatments for patients.  Read More »

Allergan PLC recently started See America, a new initiative to combat preventable blindness in the U.S. Read More »

Nationwide mail-order pharmacy giant Express Scripts recently revealed successful limits to 2016 drug spending — yielding a 27 percent decrease over that of 2015 — from St. Louis as it released its annual Drug Trend Report. Read More »

Teva Pharmaceutical Industries Ltd., recently announced their intent to market a new drug in the U.S.  Read More »